1. The Importance of Partnership in the Rollout of Triple-Drug Therapy to Eliminate Lymphatic Filariasis in the Pacific
- Author
-
Rainima-Qaniuci, M, Lepaitai, HB, Bhagirov, R, Padmasiri, E, Naseri, T, Thomsen, R, Won, KY, Brant, TA, Dodd, E, Nua, MT, Utu, F, Tufa, A, Chutaro, E, Camacho, J, Suiaunoa-Scanlan, L, Thean, LJ, Mani, J, Hardy, M, Samuela, J, Romani, L, Kaldor, J, Steer, AC, Faktaufon, D, Bechu, V, Naqio, F, Sosene, V, Sekihara, M, Otaki, J, Buhagiar, TS, Yajima, A, Rainima-Qaniuci, M, Lepaitai, HB, Bhagirov, R, Padmasiri, E, Naseri, T, Thomsen, R, Won, KY, Brant, TA, Dodd, E, Nua, MT, Utu, F, Tufa, A, Chutaro, E, Camacho, J, Suiaunoa-Scanlan, L, Thean, LJ, Mani, J, Hardy, M, Samuela, J, Romani, L, Kaldor, J, Steer, AC, Faktaufon, D, Bechu, V, Naqio, F, Sosene, V, Sekihara, M, Otaki, J, Buhagiar, TS, and Yajima, A
- Abstract
We discuss the experience of some Pacific island countries in introducing the new WHO-recommended treatment protocol for lymphatic filariasis-a triple-drug therapy composed of ivermectin, diethylcarbamazine, and albendazole. The successful rollout of the new treatment protocol was dependent on strong partnerships among these countries' ministries of health, WHO, and other stakeholders. Effective communication among these partners allowed for lessons learned to cross borders and have a positive impact on the experiences of other countries. We also describe various challenges confronted during this process and the ways these countries overcame them.
- Published
- 2022